Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer
Data(s) |
2014
|
---|---|
Resumo |
<p>AIMS: The aim of this article was to evaluate afatinib (BIBW 2992), an ErbB family blocker, and nintedanib (BIBF 1120), a triple angiokinase inhibitor, in castration-resistant prostate cancer patients.</p><p>PATIENTS & METHODS: Patients were randomized to receive nintedanib (250 mg twice daily), afatinib (40 mg once daily [q.d.]), or alternating sequential 7-day nintedanib (250 mg twice daily) and afatinib (70 mg q.d. [Combi70]), which was reduced to 40 mg q.d. (Combi40) due to adverse events. The primary end point was progression-free rate at 12 weeks.</p><p>RESULTS: Of the 85 patients treated 46, 20, 16 and three received nintedanib, afatinib, Combi40 and Combi70, respectively. At 12 weeks, the progression-free rate was 26% (seven out of 27 patients) for nintedanib, and 0% for afatinib and Combi40 groups. Two patients had a ≥50% decline in PSA (nintedanib and the Combi40 groups). The most common drug-related adverse events were diarrhea, nausea, vomiting and lethargy.</p><p>CONCLUSION: Nintedanib and/or afatinib demonstrated limited anti-tumor activity in unselected advanced castration-resistant prostate cancer patients.</p> |
Identificador | |
Idioma(s) |
eng |
Direitos |
info:eu-repo/semantics/restrictedAccess |
Fonte |
Molife , L R , Omlin , A , Jones , R J , Karavasilis , V , Bloomfield , D , Lumsden , G , Fong , P C , Olmos , D , O'Sullivan , J M , Pedley , I , Hickish , T , Jenkins , P , Thompson , E , Oommen , N , Wheatley , D , Heath , C , Temple , G , Pelling , K & de Bono , J S 2014 , ' Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer ' Future oncology (London, England) , vol 10 , no. 2 , pp. 219-31 . DOI: 10.2217/fon.13.250 |
Palavras-Chave | #Aged #Aged, 80 and over #Antineoplastic Combined Chemotherapy Protocols #Humans #Indoles #Male #Middle Aged #Neoplasm Grading #Neoplasm Metastasis #Neoplasm Staging #Prostatic Neoplasms, Castration-Resistant #Quinazolines #Treatment Outcome |
Tipo |
article |